Company Presentations Presentations Cassava Corporate Presentation – First Quarter 2024 1.8 MB Warrant Distribution Q&A – Updated January 3, 2024 236.1 KB Warrant Prospectus Supplement (as filed with SEC) Warrant Agreement Dated as of January 3, 2024 2024 Warrants – IRS Form 8937 2.5 MB CTAD 2023 “Results of a Phase 2 Randomized Withdrawal Study of Simufilam in Mild-to-moderate Alzheimer’s Disease” 3.3 MB CTAD 2023 Poster Presentation “Simufilam’s Primary Mechanism of Action Confirmed by Time-resolved FRET” 518.6 KB CTAD 2023 Poster Publication “Interim MRI Safety Analysis From a 76-week Phase 3 Clinical Trial of Simufilam in Alzheimer’s Disease” 592.4 KB CTAD 2022 Poster – A. Mammel, Neurocode 1.2 MB CTAD 2021 Poster 340.6 KB Past Events International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD 2024) Mar 5 - Mar 9, 2024 Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristics in RETHINK and REFOCUS Phase 3 Trials Supporting Materials Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristics in RETHINK and REFOCUS Phase 3 Trials 1.8 MB
CTAD 2023 “Results of a Phase 2 Randomized Withdrawal Study of Simufilam in Mild-to-moderate Alzheimer’s Disease” 3.3 MB
CTAD 2023 “Results of a Phase 2 Randomized Withdrawal Study of Simufilam in Mild-to-moderate Alzheimer’s Disease” 3.3 MB
CTAD 2023 Poster Presentation “Simufilam’s Primary Mechanism of Action Confirmed by Time-resolved FRET” 518.6 KB
CTAD 2023 Poster Presentation “Simufilam’s Primary Mechanism of Action Confirmed by Time-resolved FRET” 518.6 KB
CTAD 2023 Poster Publication “Interim MRI Safety Analysis From a 76-week Phase 3 Clinical Trial of Simufilam in Alzheimer’s Disease” 592.4 KB
CTAD 2023 Poster Publication “Interim MRI Safety Analysis From a 76-week Phase 3 Clinical Trial of Simufilam in Alzheimer’s Disease” 592.4 KB
International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD 2024) Mar 5 - Mar 9, 2024 Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristics in RETHINK and REFOCUS Phase 3 Trials Supporting Materials Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristics in RETHINK and REFOCUS Phase 3 Trials 1.8 MB
Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristics in RETHINK and REFOCUS Phase 3 Trials 1.8 MB